You just read:

Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment

News provided by

Actinium Pharmaceuticals, Inc.

Oct 28, 2019, 08:20 ET